Development Programs

Clinical Trials

In January 2007 the United States Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application for iCo-007 to treat diabetic macular edema.

iCo intends to initiate a clinical trial using iCo-007 for age-related macular degeneration and diabetic retinopathy. If you are a physician or a patient interested in participating in this study, please contact us at: